GENFIT S.A. (GNFT): Price and Financial Metrics
GET POWR RATINGS... FREE!
GNFT Stock Summary
- With a price/sales ratio of 24.3, Genfit SA has a higher such ratio than 93.84% of stocks in our set.
- With a year-over-year growth in debt of -58.19%, Genfit SA's debt growth rate surpasses only 5.84% of about US stocks.
- As for revenue growth, note that GNFT's revenue has grown -85.95% over the past 12 months; that beats the revenue growth of only 1.25% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Genfit SA are IMOS, NVEC, IPHA, SNGX, and PZG.
- Visit GNFT's SEC page to see the company's official filings. To visit the company's web site, go to www.genfit.com.
GNFT Stock Price Chart Interactive Chart >
GNFT Price/Volume Stats
|Current price||$3.45||52-week high||$6.38|
|Prev. close||$3.66||52-week low||$3.01|
|Day high||$3.55||Avg. volume||23,415|
|50-day MA||$3.75||Dividend yield||N/A|
|200-day MA||$3.86||Market Cap||171.86M|
GENFIT S.A. (GNFT) Company Bio
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.
Most Popular Stories View All
GNFT Latest News Stream
|Loading, please wait...|
GNFT Latest Social Stream
View Full GNFT Social Stream
Latest GNFT News From Around the Web
Below are the latest news stories about Genfit SA that investors may wish to consider to help them evaluate GNFT as an investment opportunity.
Lille, France; Cambridge , M A ; February 2 6 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of December 31, 2021 and revenues for 2021 1 .
Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its provisional financial calendar for 2022. February 28, 2022: Publication of revenue and cash position at December 31, 2021 April 07, 2022: Publication of Full Year 2021 financial statements The 2020 Universal Registration Document and Annual Financial Report (included in the
Lille, France; Cambridge, MA; January 21, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2021: 137,012 shares€512 873.86
The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GNFT Price Returns